blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2090304

EP2090304 - Use of sugar phosphates, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycose-enzyme complex, the malate aspartate shuttle and/or transaminases [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  24.06.2011
Database last updated on 15.07.2024
Most recent event   Tooltip24.06.2011Application deemed to be withdrawnpublished on 27.07.2011  [2011/30]
Applicant(s)For all designated states
ScheBo Biotech AG
Netanyastrasse 3-5
35394 Giessen / DE
[2009/34]
Inventor(s)01 / Eigenbrodt, Erich
Erich Kästner Straße 2
35440 Linden/Grossen Linden / DE
02 / Mazurek, Sybille
Goethestrasse 35
35440 Linden / DE
03 / Grimm, Helmut
Zur alten Eiche 19
35394 Giessen / DE
 [2009/34]
Representative(s)Jungblut, Bernhard Jakob, et al
Jungblut & Seuss
Patentanwälte
Wittestraße 30 J
13509 Berlin / DE
[N/P]
Former [2009/34]Jungblut, Bernhard Jakob, et al
JUNGBLUT & SEUSS Patentanwälte Max-Dohrn-Strasse 10
10589 Berlin / DE
Application number, filing date09075090.217.01.2002
[2009/34]
Priority number, dateDE2001101292613.03.2001         Original published format: DE 10112926
[2009/34]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report 
No.:EP2090304
Date:19.08.2009
Language:DE
[2009/34]
Type: A3 Search report 
No.:EP2090304
Date:21.07.2010
[2010/29]
Search report(s)(Supplementary) European search report - dispatched on:EP22.06.2010
ClassificationIPC:A61K31/195, A61K31/198, A61K31/401, A61K31/42, A61K31/661, A61K31/6615, A61K31/7024, A61P35/00, A61P37/06, A61P29/00
[2009/34]
CPC:
A61K31/70 (EP,US); A61K31/197 (EP,US); A61K31/198 (EP,US);
A61K31/365 (EP,US); A61K31/401 (EP,US); A61K31/661 (EP,US);
A61K31/6615 (EP,US); A61K31/7024 (EP,US); A61P29/00 (EP);
A61P35/00 (EP); A61P37/04 (EP); A61P37/06 (EP);
A61P43/00 (EP) (-)
Designated contracting states[2011/13]
Former [2009/34]AT,  BE,  CH,  CY,  DE,  DK,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE,  TR 
Extension statesAL27.02.2009
MK27.02.2009
TitleGerman:Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glykose-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen[2009/34]
English:Use of sugar phosphates, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycose-enzyme complex, the malate aspartate shuttle and/or transaminases[2009/34]
French:Utilisation de phosphates de sucre, de phosphates de sucre analogues, d'aminoacides et/ou d'aminoacides analogues en vue de la modulation du complexe glucose-enzyme, du Malate Aspartate Shuttle et/ou des transaminases[2009/34]
Examination procedure22.01.2011Application deemed to be withdrawn, date of legal effect  [2011/30]
01.03.2011Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2011/30]
Parent application(s)   TooltipEP02704608.5  / EP1368018
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020704608) is  03.06.2004
Fees paidRenewal fee
27.02.2009Renewal fee patent year 03
27.02.2009Renewal fee patent year 04
27.02.2009Renewal fee patent year 05
27.02.2009Renewal fee patent year 06
27.02.2009Renewal fee patent year 07
27.02.2009Renewal fee patent year 08
11.01.2010Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.01.201110   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]EP1002535  (IKONOMIDOU HRISSANTHI [DE]) [X] 1-2,4-5 * page 7, column 12, line 26 - line 27 * * claims 1,16,28,29 *;
 [X]DE3823735  (HAJEK ERNST [DE]) [X] 1-2,4-5 * the whole document *;
 [X]DE3440090  (NOVO MED AG [CH]) [X] 1-2,4-5 * claims 1,2 * * page 4, line 5 - line 7 * * page 5, line 9 - line 33 *;
 [X]DE3329253  (MILUPA AG [DE]) [X] 1-2,4-5 * claims 1-4 * * examples 1-14 *;
 [A]US5972628  (EIGENBRODT ERICH [DE], et al) [A] 1-2,4-5 * the whole document *;
 [X]  - MAZUREK S ET AL, "THE ROLE OF PHOSPHOMETABOLITES IN CELL PROLIFERATION, ENERGY METABOLISM, AND TUMOR THERAPY", JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, PLENUM PUBLISHING, NEW YORK, NY, US, (1997), vol. 29, no. 4, ISSN 0145-479X, pages 315 - 327, XP002940705 [X] 1-5 * page 319 * * page 326 *

DOI:   http://dx.doi.org/10.1023/A:1022490512705
 [A]  - EIGENBRODT, E., ET AL., "Pyruvate kinase and the interaction of amino acids and carbohydrate metabolism in solid tumours", ANTICANCER RESEARCH, (1998), vol. 18, pages 3267 - 3274, XP008003665 [A] 1-2,4-5 * the whole document *
 [A]  - MAZUREK, S., ET AL., "Pyruvate kinase type M2: a target of three different oncoproteins", TUMOR BIOLOGY, (2000), vol. 21 (suppl 1), page 9, XP008003664 [A] 1-2,4-5 * the whole document *
by applicant   - C.V. DANG ET AL., TIBS, (1999), vol. 24, pages 68 - 72
    - E. EIGENBRODT ET AL., Critical Reviews in Oncogenesis, CRC-PRESS, (1992), vol. 3, pages 91 - 115
    - G.E.J STAAL ET AL., Biochemical and Molecular Aspects of Selected Cancers, ACADEMIC PRESS INC., (1991), vol. 1, pages 313 - 337
    - U. BRINCK ET AL., VIRCHOWS ARCHIV, (1994), vol. 424, pages 177 - 185
    - T. NOGUCHI ET AL., J. BIOL. CHEM., (1986), vol. 261, pages 13807 - 13812
    - K. TANI ET AL., GENE, (1988), vol. 73, pages 509 - 516
    - S. MAZUREK ET AL., J. CELL. PHYSIOL., (1996), vol. 167, pages 238 - 250
    - S. MAZUREK ET AL., ANTICANCER RES., (1998), vol. 18, pages 3275 - 3282
    - S. MAZUREK ET AL., J. BIOENERG. BIOMEMBR., (1997), vol. 29, pages 315 - 330
    - E. EIGENBRODT ET AL., BIOCHEMICAL AN MOLECULAR ASPECTS OF SELECTED CANCER, (1994), vol. 2, page 311
    - EIGENBRODT ET AL., Critical Reviews in Oncogenesis, CRC-PRESS, (1992), vol. 3, pages 91 - 115
    - MANGOLD ET AL., EUR. J. BIOCHEM., (1999), vol. 266, pages 1 - 9
    - EIGENBRODT ET AL., BIOCHEMICAL AN MOLECULAR ASPECTS OF SELECTED CANCERS, (1994), vol. 2, page 311
    - NOVIKOFF B. A, "transplantatble rat liver tumor induced by 4-dimethylaminoazobenzene", CANCER RES, (1951), vol. 17, page 1010
    - "Long term intravenous infusion", WEEKS JR., Meyers RD (Hrsg.) Methods in Psychobiology, ACADEMIC PRESS, (1972), vol. 2, page 155
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.